Table 3.
All treatment-related adverse events observed in the two cohorts
| Adverse event, n (%) | Cohort 1 (n=9)
|
Cohort 2 (n=20)
|
Total (N=29)
|
|||
|---|---|---|---|---|---|---|
| All grades | Grade 3/4 | All grades | Grade 3/4 | All grades | Grade 3/4 | |
| Asthenia and/or fatigue | 7 (78) | 1 (11) | NA | 10 (50) | NA | 11 (38) |
| Mucositis | 6 (67) | 0 | NA | 3 (15) | NA | 3 (10) |
| Diarrhea | 5 (56) | 0 | NA | 2 (10) | NA | 2 (7) |
| Nausea and/or vomiting | 7 (78) | 0 | NA | 0 | NA | 0 |
| Hand–foot syndrome | 5 (56) | 1 (11) | NA | 0 | NA | 1 (3) |
| Hypertension | 5 (56) | 1 (11) | 18 (90) | 1 (5) | 23 (79) | 2 (7) |
Note: NA, not available (some of all-grade adverse-event data were not available for Cohort 2).